iSpecimen Inc.: insider trades · United States · SEC (Form 4)

About iSpecimen Inc.

iSpecimen Inc. (ticker: ISPC) is a U.S.-based life-science marketplace company listed on the Nasdaq Capital Market in the United States. Its business sits at the intersection of healthcare technology and biomedical research. iSpecimen operates the iSpecimen Marketplace®, a digital platform that connects life science researchers with providers of human biospecimens, including hospitals, biorepositories, commercial laboratories, medical groups, clinical trial organizations, and other healthcare institutions. The company’s core value proposition is to streamline the sourcing of human samples required for research while helping provider organizations unlock revenue from underutilized inventory and clinical remnants. The company was founded in 2009 and completed its first commercial sale in 2012. Its headquarters and principal executive offices are in Woburn, Massachusetts, United States, placing it within one of the most important biotechnology clusters in North America. iSpecimen’s origin story is rooted in a practical problem identified by pathologists: researchers often had to manually search fragmented clinical networks to find the right specimens. That history still defines the company today, as it aims to reduce friction in procurement, compliance, contracting, and logistics around biospecimen access. From a business-line perspective, iSpecimen focuses on several specimen categories, including biofluids, tissue, stem and immune cells, matched sets, and related patient data. The marketplace is designed to give researchers single-interface access to a broad and growing network of providers, with tools for search, ordering, fulfillment tracking, and dataset access. Its customer base is primarily composed of research institutions, biotech companies, and pharmaceutical companies seeking highly specific human samples for discovery programs, especially in oncology, cardiovascular disease, and other translational research areas. Competitively, iSpecimen differentiates itself as a specialized, technology-enabled marketplace rather than a traditional distributor. Its competitive edge depends on network breadth, data quality, workflow efficiency, and compliance handling. In a fragmented biospecimen market, those factors are critical: researchers want speed and specificity, while providers want standardized processes and a scalable path to monetization. The model is attractive in theory, but execution matters greatly because the market is operationally complex and highly regulated. Recent developments have included continued efforts to expand the supplier network and enhance marketplace functionality. Financially and at the stock level, the company has also seen notable events, including a private placement in late 2025 and a 1-for-40 reverse stock split effective in late April 2026, while its common stock continues to trade on Nasdaq under ISPC. For investors, iSpecimen remains a small-cap, growth-oriented healthcare technology name focused on increasing marketplace usage, deepening supply-side relationships, and improving commercial traction in the U.S. biospecimen market.